­­­

Joint Transnational Call for Proposals (2025)

**Pharmacogenomic strategies for personalised medicine approaches (PGxPM2025)**

(EP PerMed Grant 101137129)

Announcement

For further information, please visit our website: [**www.eppermed.eu**](http://www.eppermed.eu)

or contact the EP PerMed Joint Call Secretariat (JCS)

The German Aerospace Center e.V. – Project Management Agency, (DLR-PT)

Heinrich-Konen-Straße 1, 53227 Bonn, GERMANY

Alexandra Becker, Katja Kuhlmann

Phone: +49 (0) 228 3821 2211

PerMed@dlr.de

Announcement for the Joint Transnational Call (JTC) 2025

The **European Partnership for Personalised Medicine, EP PerMed,** supported by the European Union under Horizon Europe, Grant Agreement N° 101137129, has launched its second joint transnational call (JTC2025) for proposals on “Pharmacogenomic strategies for personalised medicine approaches (PGxPM2025)”. In total, 35 funding organisations participate in this call with an available budget of over 36.5 Mio. € (approx.).

EP PerMed funding organisations, listed below, have agreed to jointly fund multinational innovative research projects in personalised medicine (PM), which should bring together academic, clinical/public health and private research teams, thus enhancing the competitiveness in Europe in this field.

The call will be implemented in two stages, i.e. a pre- and a full-proposal phase.

Expected timeline of the call

|  |  |
| --- | --- |
| **16 December, 2024** | Publication of the call |
| **09 January 2025** | JTC2025 information day  <https://www.eppermed.eu/news-events/events/ep-permed-jtc2025-information-day/> |
| **04 February 2025 (23:00, CET)** | Complete SAMRC Pre-Eligibility check online [**https://redcap.link/Pre-EligibilityCheck**](https://redcap.link/Pre-EligibilityCheck) |
| **18 February 2025 (14:00, CET)** | Deadline for pre-proposal submission [PT-Outline](https://ptoutline.eu/app/EPPERMED2025) |
| **Expected around 15 May, 2025** | Communication of the results of the pre-proposal assessment and invitation to the full-proposal stage |
| **17 June, 2025 (14:00, CEST)** | Deadline for full-proposal submission |
| **Mid/end of August 2025** | Rebuttal stage |
| **Expected for October 2025** | Communication of the funding decisions to the applicants |
| **End of 2025, beginning of 2026** | Expected project start (according to regional/national funding regulations) |

Electronic submission website

Electronic proposal submission is mandatory on [PT-Outline](https://ptoutline.eu/app/EPPERMED2025). Research project consortia who intend to submit a transnational proposal should register as soon as possible, by clicking on **“Sign up”** and follow further instructions.

Contact persons for the Joint Call Secretariat (JCS)

The **EP PerMed JCS** is hosted by the **German Aerospace Center e.V. – Project Management Agency, (DLR-PT)**:

Alexandra Becker and Katja Kuhlmann  
Heinrich-Konen-Straße 1, 53227 Bonn, Germany  
Phone: +49 (0) 228 3821 2211  
Email: [permed@dlr.de](mailto:permed@dlr.de)

Call Documents

The call text and all additional documents can be downloaded below:

SAMRC Pre-eligibility Check form to be completed by South African Applicants

Actual Link <https://redcap.link/Pre-EligibilityCheck>

[Call text (PDF)](https://www.eppermed.eu/wp-content/uploads/EPPerMed_JTC2025_Call_Text.pdf)

Actual link: <https://www.eppermed.eu/wp-content/uploads/EPPerMed_JTC2025_Call_Text.pdf>

[Guidelines for applicants (PDF)](https://www.eppermed.eu/wp-content/uploads/EPPerMed_JTC2025_GuidelinesApplicants.pdf)

Actual link: <https://www.eppermed.eu/wp-content/uploads/EPPerMed_JTC2025_GuidelinesApplicants.pdf>

[Pre-proposal form (DOCX)](https://www.eppermed.eu/wp-content/uploads/EPPerMed_JTC2025_pre-proposal_form.docx)

Actual link: <https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.eppermed.eu%2Fwp-content%2Fuploads%2FEPPerMed_JTC2025_pre-proposal_form.docx&wdOrigin=BROWSELINK>

Aims of the Call

The overall objectives of the JTC2025 will be to

* Support research projects in human health on pharmacogenomic strategies for personalised medicine approaches that address one or more of the following aspects:
  + **identification of new pharmacogenomic markers or signatures using (multi)-omics data in relation to drug or drug combination.**
  + **validation of a pharmacogenomic marker or signatures using (multi)-omics data in predicting drug or drug combination outcomes.**
  + **use pharmaco-omics strategies to determine the right dosage, the efficacy of treatments and/or the risk of adverse drug response and non-response to treatment to tailor personalised treatment pathways, including combined treatments (multi-medication).**
* Encourage and enable interdisciplinary collaborations, i.e. multi-actor research by engaging a range of other relevant disciplines such as pre-clinical and clinical research, bioinformatics/health informatics/data research, ELSA research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to support the implementation of the research outcomes into clinical practice.
* Encourage cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises), industry, as well as regulatory/HTA agencies and patient organisations.
* Establish participatory research, i.e. active representation of patients or citizens as part of research projects.

Projects are encouraged to **combine the following aspects** in their research:

1. Omics data such as epigenomics, transcriptomics, proteomics and metabolomics data in addition to genomics data in relation to treatment outcomes. A key goal is to assess the importance of one or more -omics approaches (multi-modal approaches) in optimising treatment outcomes.
2. Information regarding patient medication (prescription and non-prescription), dose or compliance.
3. Information (including clinical and environmental factors) regarding medication efficacy, adverse effects and patient reported outcomes (PRO).

**Participatory research should be established** in that active representation of patients or citizens is part of research projects. EP PerMed is supporting this approach by providing dedicated funding to organisations representing patients or citizens to participate as partners in proposals submitted to this call. Those organisations could support in designing the research, ensuring that research questions are relevant from the patients’ and citizens’ point of view. They might also support in collecting data for PROs and adverse effects.

Projects funded under this call are furthermore required to **include a dedicated work package focussing on the question of implementation of the research outcomes** into clinical practice with a focus on e.g. patient outcome, costs, reimbursement, education, ELSA (ethical, legal and societal aspect) or feasible use at the point of care.

Research projects in all disease areas are welcome. Research on polygenic drug response phenotypes is encouraged.

**Exclusion: Projects focussing only on drug-drug-interaction are out of scope. Projects focusing on the clinical development of new drugs are out scope.**

Please refer to the Call Text of the JTC2025 for further information and definitions.

General (Eligibility) Conditions for Application

Joint research proposals may be submitted by applicants belonging to an entity according to the following categories (subject to regional/national funding regulations; see “Guidelines for Applicants”):

1. **Academia** (research teams working in universities, other higher education institutions) **or research institutes;**
2. **Clinical/public health sector** (research teams working in hospitals/public health and/or other healthcare settings and health organisations). Participation of clinicians (e.g. medical doctors, nurses), pharmacists and general practitioners in the research teams is encouraged;
3. **Private for-profit (industry) partners, e.g. SME**[[1]](#footnote-1)(small and medium-sized enterprises) **and private non-profit partners**, e.g. foundations, associations or non-governmental organisations.

**Consortia submitting applications to this call are strongly encouraged to include partners from different categories (A, B and C) in line with the crosscutting/multidisciplinary nature of the call.**

Only transnational projects will be funded. **Each consortium must involve at least three partners from three different EU Member States or Associated Countries whose funding organisations participate in the call. Each of these partners must be eligible and request funding from the respective funding organisation.** All three legal entities must be independent of each other**. The project coordinator must be eligible to be funded** by his/her regional/national participating funding organisation. The project coordinator (i.e. principal investigator and organisation) cannot be changed between the first and second stage.

**Max. 2 project partners per consortium can request funding from the same funding organisation.** For some funding organisations, the maximum number of eligible partners who can be funded in one project is limited to one (see also “Guidelines for Applicants” for individual funding rules).

**No more than one partner with their own funding is allowed** in the consortia with at least three partners eligible for funding (more indications in the Call Text: “B. Funding recipients”, section 7).

**Pre-proposal stage:** Maximum number of partners is 6 (no more than 2 partners from the same country including partners on own funding); Maximum number of partners can be 7 if the consortium includes a 3rd partner of the same country (condition: funding requested from at least 2 different funders of the respective country; applies to only one country per consortium; including partners on own funding).

**Widening concept:** Consortia are allowed to include in the full-proposal phase an additional project partner that is eligible to receive funding from a funding organisation that is underrepresented in the second stage of the call and that agrees to participate in the widening option (a list of underrepresented regions/countries will be provided to coordinators invited to submit full-proposals).

**Exception:** To facilitate the integration of organisations representing patients or citizens in consortia, they can be added as additional partners at the pre-proposal stage or full-proposal stage. Organisations representing patients or citizens can be added as additional partner(s) either on own funds or by applying for funding, if eligible, from EP PerMed (see page 10) or the respective funding organisations. The consortia must follow all of the above-mentioned rules regarding the consortia composition without counting the patient/citizen representing organisations, except for the following rule: **within one consortium, no more than 2 partners can request funding from the same funding organisation, including patient/citizen organisations.** For some funding organisations, the maximum number of eligible partners who can be funded in one project is one.

Each project partner has to be represented by **one principal investigator**. Within a joint proposal, each project partner’s principal investigator will be the contact person for the JCS and the relevant regional/national funding organisation. Each consortium must nominate one **project coordinator** among the project’s principal investigators. The nomination of a project co-coordinator is not allowed.

If a **partner** is found to be ineligible by one of the funding organisations after the formal check, the entire proposal may be rejected without further review. For a definition of eligible partners, see “Guidelines for Applicants”, the regional/national regulations, and contact the concerned regional/national funding organisation.

A maximum project duration of 3 years may be applied for.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Number of partners in the proposal\*** | **Pre-proposal** | | | | | **Full-proposal**  (only by inclusion of one underrepresented region/country) |
| **3** | **4** | **5** | **6** | **7** | **+1** |
| Maximum number of partners with own funding\*\* | 0 | 1 | 1 | 1 | 1 | 1 |
| Maximum number of partners per country\*\*\* | 1 | 2 | 2 | 2 | 3 | 3 (for consortia with 8 partners) |

\* at least three partners being eligible and request funding from three different EU Member States or Associated Countries whose funding organisations participate in the call. Patient/citizen representing organisations are not included in this calculation.

\*\* patient/citizen representing organisations are not included in this calculation and can be added as partners participating with own funding at the pre- and full-proposal stage.

\*\*\* patient/citizen representing organisations are not included in this calculation and can be added as additional partners in the pre-proposal or full-proposal stage. They can participate either on own funds or apply for funding, if eligible, from the regional/national funding organisation or EP PerMed. Please note: **within one consortium, not more than 2 partners can request funding from the same funding organisation, including patient/citizen organisations.** For some funding agencies, the maximum number of eligible partners who can be funded in one project is one.

All eligibility criteria and submission requirements are detailed in the following two call documents: “Call text” and the “Guidelines for Applicants”.

|  |
| --- |
| Whilst applications will be submitted jointly by groups from several countries, individual groups will be funded by the individual EP PerMed funding organisation respective of the region/country from which applicants applies. The applications are therefore subject to eligibility criteria and regulations of individual funding organisations. Applicants are strongly advised to contact their regional/ national representatives of the participating relevant funding organisation as soon as possible in order to confirm their eligibility (see also below “*Contact details of participating members*”). |

SOUTH AFRICAN SPECIFIC GUIDELINES

|  |  |
| --- | --- |
| Funding Organisation | **The South African Medical Research Council, (SAMRC)** |
| Initial funding  pre-commitment | EUR 632.000 (ZAR 12.050.300)  Fund 3 to 4 projects up to EUR 160.000 per project (excluding Value Added Tax (VAT) and including a 5% overhead cost) |
| Regional/National contact for the EP PerMed JTC2025 | Rizwana Mia  Senior Program Manager – Precision Medicine  SAMRC - GRANTS INNOVATION & PRODUCT DEVELOPMENT  Francie Van Zijl Drive, Parow Valley, 7501  Tel.: +27 21 938 0984  Email: Rizwana.Mia@mrc.ac.za |
| Eligible institutions | South African universities, academic hospitals and other public or independent research organisations. This call will allow private entities to respond. |
| Additional eligibility  criteria | **Only South African citizens or permanent residents are eligible for SAMRC funding.**  **Private non-profit or Private for-profit entities such as** **Small Medium Micro Enterprise’s** (**SMME’s**) **registered as a South African company under the Company’s Act are eligible to apply.** <https://www.gov.za/sites/default/files/gcis_document/201903/423041gon399.pdf>  The company’s SMME status must meet the requirements as stated by the definition of the South African National Small Enterprise Act, No. 102 of 1996. The eligibility criterion for a company to gain access to public entity funding is subject to meet the following requirements:   1. Submit a valid CIPC company registration certificate and (Broad-Based-Black-Economic Equity (BBBEE) certification status 2. Submit a tax clearance certificate issued by the South African Revenue Service. 3. Submit a financial status report (this should include a company balance sheet and financial income/ expense statements), to show that its financial status is adequate to hold project funding and the entity follows an audit process for usage and monitoring of funds. 4. The company directors may also be subject to a personal credit status check.   A due diligence process will be executed to verify such information at the time of the award. |
| Eligible costs | Allowable costs include the following (all direct line items must be auditable):   * Personnel: Soft-funded posts for individuals working on the project (e.g. post-docs, students, technicians, project managers) will be funded, provided an accurate estimation of time allocation is provided and they are not already funded from other means. * Consultants: These may include both local and/or foreign consultants who provide a service or capability that is not available among the project partners but is essential for the completion of project deliverables. * Equipment: Partial or full support for the cost of equipment may, in some instances, be requested, provided that it is directly required for the project. A budget limitation may apply. * Laboratory costs: consumables and other direct laboratory or research costs. * Sub-contracts: These may be to any local or international organization that provides a service or capability that is not available among the project partners but is essential for the completion of South African project deliverables. * Travel and accommodation that is directly related to the execution of the project. * Institutional overhead: An indirect costs rate of 5% is allowed.   If research equipment is purchased using SAMRC funding, unless specified otherwise by the specific funding mechanism, it becomes the property of the host institution. Under no circumstances may equipment become the property of the individual researcher to whom the funding was allocated. The equipment may not be removed from the host institution and/or transferred to another institution without the express written approval of the host institution and concurrence by the SAMRC. The institution must take responsibility for any necessary maintenance of and insurance on the equipment.  Budgets must be aligned to achievement of milestones and deliverables. The disbursement schedule will proceed with an upfront payment upon signature of the SAMRC funding agreement. Subsequent disbursements are subject to project progress based on achievement of milestones and deliverables, as well as adequate usage (up to 70%) of the previous disbursement. |
| Funding of public-private partnerships allowed | Yes, subject to the due diligence process stated above.  Applicants will be contacted directly regarding this process. |
| Further guidance | Non-allowable costs include the following:   * Salaries of permanent or fixed term staff, e.g. tenured staff, professors etc., that are fully covered by the host institutions as well as permanent staff members from private entities. * Purchase or construction of a building. * Rental costs for space that is owned by the institutions/ private entities participating in the project. * Recruitment or retrenchment costs for staff. * Purchase of office furniture.   The South African Applicant will have to complete separate annexures for the SAMRC Funding agreement. Annexure A- Adapted South African Project Proposal template and Annexure B -Project Budget template will be provided for completion upon award. These two annexures will be appended to the SAMRC Funding agreement and utilized to monitor and evaluate project progress.  The SAMRC has a bi-annual reporting procedure. Each reporting period will be followed by the submission of progress and finance reports. The SAMRC will adhere to annual funding disbursements. Private entities will be subject to six monthly disbursement schedules.  For more detail on the general terms and conditions for SAMRC funding please refer to the SAMRC terms and conditions of funding, use the following link: [Microsoft Word - SAMRC Terms and Conditions of Funding 2024 Clean](https://www.samrc.ac.za/sites/default/files/attachments/2024-09/SAMRC%20Terms%20and%20Conditions%20of%20Funding.pdf)  **Any publications press releases and other documents which include results obtained in the project must acknowledge the funding source as follows: “*Research reported in this [publication/press release] was supported by the South African Medical Research Council with funds received from the South African Department of Science and Innovation”.* Any publications that do not include this acknowledgement will not be accepted as outputs of the project.**  **Requirements on data and repositories:**  The SAMRC strongly encourages open access to research outputs/data to be made available in recognized publicly available databases. The SAMRC conforms to Plan S -supported by cOAlition S, an international consortium of research funding and performing organisations. Plan S requires that, from 2021, scientific publications that result from research funded by public grants must be published in compliant Open Access journals or platforms.  **Regulatory and Ethical Compliance**: All SAMRC grantees are required to obtain approval for any research involving human or animal subjects or samples therefrom the appropriate institutional review board or ethics committee and provide the SAMRC with a copy of such approval prior to undertaking the research. This requirement extends to all sites participating in the research. Any such research must, in addition to ethical approval compliance, be conducted in accordance with the generally accepted principles of “Good Clinical Practices”, which shall include but not be limited to, requiring prior informed consent from the human subjects and shall be conducted in accordance with all applicable national and international regulations and guidelines pertaining to research involving human subjects, management of data confidentiality, research involving animals, use or release of genetically modified organisms, research use of recombinant DNA, and/or use of any organism, substance or material considered to be a biohazard, including adherence to all applicable standards for transport of specimens, both locally and internationally, as appropriate. This also applies to the development of data repositories and the ongoing compliance to the Protection of Personal Information Act 4 of 2013.  **Compliance to South African Regulation:**  **Ownership of any intellectual property (IP)** and associated rights arising from SAMRC-funded projects (Foreground IP) shall be determined in accordance with the provisions of the Intellectual Property Rights from Publicly Financed Research and Development Act, 51 of 2008 and associated regulations as amended from time to time (IPR Act) and the institution’s Intellectual Property Policy. The institution/ private entity is obliged to appropriately protect, manage, and commercialize the Foreground IP in accordance with all applicable provisions of the IPR Act and, in consultation with the SAMRC. The institution / Principal Investigator is required to report any Foreground IP developed to the SAMRC as part of the reporting requirements.  Project’s processing/ handling any personal information will each comply with the provisions of the **PROTECTION OF PERSONAL INFORMATION ACT 4 OF 2013** (**POPIA**). The institution/ private entity is obliged to appropriately protect and manage all personal information.  **Additional Partnership criteria**  *Aligned with the concerns raised by South Africa in its ongoing case before the International Court of Justice (ICJ) regarding Israel, the SAMRC will not support eligible South African applications involving co-applicants from the Israel Chief Scientist Office of the Ministry of Health (CSO-MOH) in this Joint Transnational Call 2025.* |

EP PerMed Partnering Tool

The new partnering tool <https://www.b2match.com/e/eppermed-partnering> will open soon.

Contact details of participating members

The following countries (24) are participating in the call: Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, Norway, Poland, Portugal, South Africa, Spain, Sweden and Turkiye (contact list is provided below and in Annex 1 of the Call Text as well as the “Guidelines for Applicants” document).

Besides national funders, the following regions are participating (10): Flanders (Belgium), Wallonia-Brussels Federation (Belgium), Saxony (Germany), Lombardy (Italy), Tuscany (Italy), Azores (Portugal), Centro Region (Portugal), Andalusia (Spain), Catalonia (Spain) and Navarre (Spain).

**Contact list**

| ***Name of participating organisation*** | ***Country/Region*** | ***Regional/National contact*** |
| --- | --- | --- |
| ***Austrian Science Fund, (FWF)*** | Austria | Hannes Zwickl  hannes.zwickl@fwf.ac.at  Tel.: +43 676 83487 8219  Heike Höller  [heike.hoeller@fwf.ac.at](mailto:heike.hoeller@fwf.ac.at)  Tel: +43 676 83487 8220 |
| ***The Research Foundation – Flanders, (FWO)*** | Belgium (Flanders) | Toon Monbaliu (FO)  Kristien Peeters (SBO)  europe@fwo.be  Tel.: +32 (0)2 550 15 70  Tel.: +32 (0)2 550 15 95 |
| ***Fund for Scientific Research – FNRS, (F.R.S.-FNRS)*** | Belgium  (Wallonia-Brussels Federation) | Maxime Bonsir  international@frs-fnrs.be  Tel.: +32 2504 9236 |
| ***The Ministry of Health of the Czech Republic / Czech Health Research Council, (MZCR/AZVCR)*** | Czech Republic | Monika Kocmanova  [Monika.kocmanova@azvcr.cz](mailto:Monika.kocmanova@azvcr.cz)  Tel.: +420 606 273 871 |
| ***Innovation Fund Denmark, (IFD)*** | Denmark | Katrine Boeriis  katrine.boeriis@innofond.dk  [internationale@innofond.dk](mailto:internationale@innofond.dk)  Tel.: +45 61 90 50 06 |
| ***Estonian Ministry of Social Affairs,  (MoSAE)*** | Estonia | Mari Teesalu  Mari.teesalu@sm.ee  Tel.: +372 5916 2047 |
| ***Estonian Research Council, (ETAG)*** | Estonia | Margit Suuroja  Margit.Suuroja@etag.ee  Tel.: +372 731 7360  Argo Soon  Argo.Soon@etag.ee  Tel.: +372 515 3424 |
| ***Business Finland, (BFRK)*** | Finland | Norma Jäppinen  norma.jappinen@businessfinland.fi Matti Hiltunen  matti.hiltunen@businessfinland.fi  Tel.: +358 50 5577 012  Tel.: +358 50 5577 652 |
| ***Agence Nationale de la Recherche, (ANR)*** | France | Monika Frenzel  Mylène Vaillancourt  EPPerMed@agencerecherche.fr  Tel: (+33) (0) 1 73 54 83 32 |
| ***Federal Ministry of Education and Research, (BMBF) German Aerospace Center e.V. – Project Management Agency, (DLR)*** | Germany | Ute Preuss  Jacqueline Kalb  permed@dlr.de  Tel.: +49 228 3821-2211 |
| ***Federal Ministry of Health, (BMG)***  ***German Aerospace Center e.V. – Project Management Agency, (DLR)*** | Germany | Fabian Gondorf  permed@dlr.de  Tel.: +49 228 3821-2211 |
| ***Saxon State Ministry for Science, Culture and Tourism, (SMWK)*** | Germany (Saxony) | Gabriele Süptitz  gabriele.sueptitz@smwk.sachsen.de Tel.: +49 351 564-64210  Caroline Karapanos  caroline.karapanos@smwk.sachsen.de Tel.: +49 351 564-64210 |
| ***General Secretariat for Research & innovation, (GRST)*** | Greece | Soon available |
| ***National Research, Development and Innovation Office, (NKFIH)*** | Hungary | Zsuzsanna Kürti  nemzetkozi@nkfih.gov.hu  zsuzsanna.kurti@nkfih.gov.hu  Tel.: +36 70 375 0036 |
| ***The Icelandic Centre for Research, (RANNIS)*** | Iceland | Helga Snævarr Kristjánsdóttir  Helga.s.kristjansdottir@rannis.is |
| ***Taighde Éireann-Research Ireland, (TE-RI)*** | Ireland | Emma McGrath  Emma.mcgrath@researchireland.ie  [eu-Cofund@sfi.ie](mailto:eu-Cofund@sfi.ie)  Tel.: +353 86 1991351 |
| ***Chief Scientist Office, Ministry of Health, (CSO-MOH)*** | Israel | Liron Even-Faitelson  [Liron.ef@moh.gov.il](mailto:Liron.ef@moh.gov.il)  Tel.: +972-2-5082168 |
| ***Italian Ministry of Health, (IT-MoH)*** | Italy | Maria Josefina Ruiz Alvarez  [mj.ruizalvarez-esterno@sanita.it](mailto:mj.ruizalvarez-esterno@sanita.it)  Tel.: (+39) 06-4990 6836  Chiara Ciccarelli  [c.ciccarelli@sanita.it](mailto:c.ciccarelli@sanita.it)  Tel.: (+39) 06-5994 3919 |
| ***Fondazione Regionale per la Ricerca Biomedica, (FRRB)*** | Italy (Lombardy) | Giulia Maria Rossignolo  [bandi@frrb.it](mailto:bandi@frrb.it)  Tel.: +39 0267650159 |
| ***Tuscany Region, (RT)*** | Italy (Tuscany) | Donatella Tanini  Teresa Vieri  eppermed@regione.toscana.it  Tel.: +39 055 4383256  Tel.: +39 055 4383289 |
| ***Latvian Council of Science, (LZP)*** | Latvia | Uldis Berkis  [Uldis.Berkis@lzp.gov.lv](mailto:Uldis.Berkis@lzp.gov.lv)  Tel.: +37129472349 |
| ***Research Council of Lithuania, (LMT)*** | Lithuania | Živilė Ruželė  [zivile.ruzele@lmt.lt](mailto:zivile.ruzele@lmt.lt)  Tel.: (+370) 676 14383 |
| ***Luxembourg National Research Fund, (FNR)*** | Luxembourg | Gideon Gießelmann  gideon.giesselmann@fnr.lu  Tel.: +352 691 362 805 |
| ***The Research Council of Norway, (RCN)*** | Norway | Katrine Rolid  karo@rcn.no  Tel.: +47 415 48 328 |
| ***National Centre for Research and Development, (NCBR)*** | Poland | Anna Stępień  [anna.stepien@ncbr.gov.pl](mailto:anna.stepien@ncbr.gov.pl)  Tel.: +48 22 39 07 210 |
| ***Fundação para a Ciência e a Tecnologia, (FCT)*** | Portugal | Rita Cavaleiro  Pedro Ferreira  [EPPerMed@fct.pt](mailto:EPPerMed@fct.pt)  Tel.: +351 213 911 541  Tel.: +351 213 924 445 |
| ***Vice-Presidency of Azores Regional Government, (VP-GRA)*** | Portugal (Azores) | Maria Vale  Tel.: +351 296 308 922  Maria.LA.Vale@azores.gov.pt |
| ***Comissão de Coordenação e Desenvolvimento Regional do Centro, (CCDRC)*** | Portugal (Centro Region) | Sophie Patrício  Dora Cabete  [ccdrc.projects@ccdrc.pt](mailto:ccdrc.projects@ccdrc.pt)  Tel.: +351 239400100 |
| ***The South African Medical Research Council, (SAMRC)*** | South Africa | Rizwana Mia  Rizwana.Mia@mrc.ac.za  Tel: +27 21 938 0984 |
| ***National Institute of Health Carlos III, (ISCIII)*** | Spain | María Callejo Arranz  [mcallejo@isciii.es](mailto:mcallejo@isciii.es)  Tel.: +34918222503 |
| ***Consejería de Salud y Consumo de la Junta de Andalucía, (CSCJA)*** | Spain (Andalusia) | Alicia Milano Curto  [ep.fps@juntadeandalucia.es](mailto:ep.fps@juntadeandalucia.es) |
| ***Health Department – Generalitat de Catalunya, (DS-CAT)*** | Spain (Catalonia) | Montserrat Llavayol  [peris@gencat.cat](mailto:peris@gencat.cat)  Tel.: +34 935566103 |
| ***Government of Navarre, (CFN)*** | Spain (Navarre) | Javier Rodrigo  [Javier.rodrigo.aznarez@navarra.es](mailto:Javier.rodrigo.aznarez@navarra.es)  Tel.: +34 848 42 76 69 |
| ***Sweden´s Innovation Agency,  (VINNOVA)*** | Sweden | Malin Eklund  Malin.eklund@Vinnova.se Tel.: +46 730 20 39 53  Casper Ullsten-Wahlund  casper.ullsten-wahlund@vinnova.se  Tel.: +46 8 473 32 06 |
| ***The Scientific and Technological Research Council of Turkey, (TUBITAK)*** | Turkiye | N. Selcan TÜRKER  selcan.turker@tubitak.gov.tr  Tel.: +90 312 298 1760 |

1. <https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en> [↑](#footnote-ref-1)